LON:AZN AstraZeneca (AZN) Share Price, News & Analysis £118.10 -66.00 (-0.56%) As of 12:31 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainabilityBuy This Stock About AstraZeneca Stock (LON:AZN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AstraZeneca alerts:Sign Up Key Stats Today's Range£117.70▼£119.1650-Day Range£101.20▼£120.4852-Week Range 9,573.51▼£133.88Volume1.08 million shsAverage Volume10.22 million shsMarket Capitalization£227.23 billionP/E Ratio32.37Dividend Yield1.98%Price TargetGBX 9,660Consensus RatingModerate Buy Company Overview AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca. Read More AstraZeneca Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScoreAZN MarketRank™: AstraZeneca scored higher than 36% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.4 / 5Analyst RatingModerate Buy Consensus RatingAstraZeneca has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAstraZeneca has only been the subject of 2 research reports in the past 90 days.Read more about AstraZeneca's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of AstraZeneca is 32.37, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 28.70.Price to Earnings Ratio vs. SectorThe P/E ratio of AstraZeneca is 32.37, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 31.31.Price to Earnings Growth RatioAstraZeneca has a PEG Ratio of 0.86. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioAstraZeneca has a P/B Ratio of 4.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for AZN. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldAstraZeneca pays a meaningful dividend of 1.23%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthAstraZeneca does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of AstraZeneca is 64.14%. This payout ratio is at a healthy, sustainable level, below 75%.Read more about AstraZeneca's dividend. Sustainability and ESG4.0 / 5Environmental Score-2.35 Short InterestThere is no current short interest data available for AZN. News and Social Media1.9 / 5News Sentiment0.44 News SentimentAstraZeneca has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for AstraZeneca this week, compared to 4 articles on an average week.Search InterestOnly 36 people have searched for AZN on MarketBeat in the last 30 days. This is a decrease of -8% compared to the previous 30 days.MarketBeat Follows3 people have added AstraZeneca to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, AstraZeneca insiders have sold more of their company's stock than they have bought. Specifically, they have bought GBX 0 in company stock and sold £1,100,892.56 in company stock.Percentage Held by InsidersOnly 0.04% of the stock of AstraZeneca is held by insiders.Percentage Held by Institutions51.03% of the stock of AstraZeneca is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AstraZeneca's insider trading history. Receive AZN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AZN Stock News HeadlinesAstraZeneca PLC (LON:AZN) Insider Aradhana Sarin Sells 9,563 SharesAugust 19, 2025 | insidertrades.comAstraZeneca PLC (AZN) Oncology Sales Hit $12B in H1 2025August 28 at 6:31 AM | insidermonkey.com“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.August 28 at 2:00 AM | Weiss Ratings (Ad)Sweden's Wallenberg groups launch joint AI companyAugust 22, 2025 | msn.comThe Capital Group Adjusts AstraZeneca HoldingsAugust 21, 2025 | tipranks.comAstraZeneca advances Wednesday, outperforms marketAugust 20, 2025 | marketwatch.comAradhana Sarin Sells 9,563 Shares of AstraZeneca (LON:AZN) StockAugust 20, 2025 | americanbankingnews.comAstraZeneca rises Monday, outperforms marketAugust 19, 2025 | marketwatch.comSee More Headlines AZN Stock Analysis - Frequently Asked Questions How have AZN shares performed this year? AstraZeneca's stock was trading at £104.68 on January 1st, 2025. Since then, AZN shares have increased by 12.8% and is now trading at £118.10. How do I buy shares of AstraZeneca? Shares of AZN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of AstraZeneca own? Based on aggregate information from My MarketBeat watchlists, some other companies that AstraZeneca investors own include GSK (GSK), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Intel (INTC), Advanced Micro Devices (AMD) and Johnson & Johnson (JNJ). Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - General Sub-IndustryPharmaceutical Products Current SymbolLON:AZN CIKN/A Webwww.astrazeneca.com Phone+44-20-73045000FaxN/AEmployees83,500Year FoundedN/APrice Target and Rating Average Price Target for AstraZenecaGBX 9,660 High Price Target£140 Low Price TargetGBX 140 Potential Upside/Downside-18.2%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)GBX 364.83 Trailing P/E Ratio32.37 Forward P/E Ratio16.19 P/E Growth0.86Net Income£8.71 billion Net Margins13.01% Pretax MarginN/A Return on Equity17.76% Return on Assets7.68% Debt Debt-to-Equity Ratio73.83 Current Ratio0.93 Quick Ratio0.59 Sales & Book Value Annual Sales£66.95 billion Price / Sales3.39 Cash FlowGBX 303.67 per share Price / Cash Flow38.89 Book ValueGBX 2,630 per share Price / Book4.49Miscellaneous Outstanding Shares1,924,030,520Free FloatN/AMarket Cap£227.23 billion OptionableNot Optionable Beta0.17 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (LON:AZN) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredTrump's "Big Beautiful Bill" hides ugly truthWashington’s new “Big Beautiful Bill” promises tax breaks… but the fine print tells a different story: trillio...Defi Master | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AstraZeneca PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share AstraZeneca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.